This project aims to develop an early stage detection of preeclampsia that will be based on the Surface Enhanced Raman Scattering (SERS) Homogenous No-Wash (HNW) platform enabling detection of clinically validated biomarkers without pre-processing or washing from a complex sample in a point-of-care setting. Clinical performance will be assessed using non-invasive urine specimens and optimized assay algorithms to improve specificity for interventions recommended by the World Health Organization (WHO). SERS HNW is an innovative multiplex, low-cost, point-of-care SERS HNW test for prediction of preeclampsia risk. Most of the WHO ASSURED criteria are met using the Surface Enhanced Raman Scattering (SERS) Homogenous No-Wash (HNW) platform. SERS HNW provides ELISA-like analytical sensitivity, is low-cost ( $1.00 per test), semi-quantitative, requires minimal training, and has the ability to multiplex pathophysiological biomarkers. Multiplex capabilities in the platform provide the potential to detect maternal/antenatal disease beyond preeclampsia.
More information about Saving Lives at Birth (Round 4)